An observational study in Cardiac Disease, sponsored by Abbott Medical Devices. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-03.
Sponsored by Abbott Medical Devices (part of Abbott) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Heart Diseases by Abbott — 5 open to participants now, 5 under way, none of them phase 3. Heart Diseases · Abbott.
Among the 15 studies in Heart Diseases by Abbott, this one is one of 2 that started in 2025, is one of 6 observational ones, and was the 13th registered.
2,135 studies on the registry are indexed under Heart Diseases; 251 are open to participants now.
Browse Heart Diseases studies →5 of the 15 studies in Heart Diseases by Abbott are open now, in 12 countries. Recruiting first, the newest first:
Abbott Medical Devices · Sites in Brazil, France, Germany and 6 more countries
Ages 18+
Abbott Medical Devices · Sites in United States, Austria, Czechia and 5 more countries
Ages 18+
Abbott Medical Devices · Sites in United States, Denmark, Estonia and 7 more countries
Abbott Medical Devices · Sites in United States, Australia, Belgium and 10 more countries
Ages 18+
By country, each count listing its studies:
Of the 182 Heart Diseases studies recruiting now, 129 (71%) set no upper age limit and 21 (12%) stop at 75 or younger; 33 take children under 18; 42 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2025.
This study's planned enrollment of 80 is below the median of 350 across 592 observational studies indexed under Heart Diseases.
Median enrollment 525 across the 8 interventional studies, 81 across the 6 observational. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Abbott Medical Devices, one of the names counted as Abbott. Under that name alone:
Abbott Medical Devices is the lead sponsor of 540 studies on the registry; 34 are open to participants now.
Of its 53 completed or terminated interventional studies of FDA-regulated products, 44 (83%) have results posted.
3 of the studies in Heart Diseases by Abbott that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06595615Abbott Medical DevicesHealth App Data Collection Study | 2027-01 |
| NCT05932615Abbott Medical DevicesENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation | 2027-04 |
| NCT07217392Abbott Medical DevicesLeft Bundle Branch Area Pacing (LBBAP) PMCF Study | 2027-04-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 15 studies in Heart Diseases by Abbott, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Utilization of additional wearable data to improve clinical outcome
In addition to information available from cardiac implantable medical devices, health related data available from commercially approved wearables and devices such as Apple watch, blood pressure monitor and scales could be used to improve predictive analytics of impending clinical events. This study is to merge implantable medical device data with wearable data to evaluate the added benefit of extra data.
Patients indicated for cardiac implantable medical devices
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Standard of care patients indicated for the devices
Acquisition of additional health data using patient App
Health data acquisition via an app from multiple wearables and externals.
Time frame: 12 months
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2025 (actual). Primary completion is estimated for Jan 2027, 21 months after the start.
Of 54 industry-sponsored observational studies under Heart Diseases, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 65. This study's planned 21 months is below that.
Counting every sponsor, half of 239 studies reached it within 46 months; a quarter within 18 and three quarters within 95.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.